HK Stock Market Move | INSILICO(03696) rises over 4%; achieves first milestone in AI drug discovery collaboration with Servier; company's PCC output sets a new record.

date
11:05 20/10/2026
avatar
GMT Eight
INSILICO Medicine (03696) rose over 4%, up 4.04% as of press time, at HK$40.68, with a turnover of HK$278 million.
INSILICO(03696) rose over 4%, up 4.04% as of press time, at HK$40.68, with a turnover of HK$278 million. On the news front, INSILICO announced this morning that the company has achieved an early drug discovery milestone in its multi-year AI-driven drug discovery collaboration with Servier, triggering a milestone payment from Servier of an undisclosed amount. This multi-year R&D collaboration, first announced in early 2026, has a total value of up to US$888 million, including US$32 million in upfront and near-term R&D milestone payments. Notably, leveraging the broad global recognition of its AI platform and pipeline assets, INSILICO achieved total revenue of approximately US$106 million in the first half of this year, a year-on-year increase of 287%; it also achieved adjusted net profit of over US$51 million, marking its first profitable half-year since listing. To date, INSILICO has nominated 11 preclinical candidate compounds (PCCs) in the first 10 months of 2026, setting a new record for the company's annual pipeline output.